JP2019529433A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529433A5
JP2019529433A5 JP2019515291A JP2019515291A JP2019529433A5 JP 2019529433 A5 JP2019529433 A5 JP 2019529433A5 JP 2019515291 A JP2019515291 A JP 2019515291A JP 2019515291 A JP2019515291 A JP 2019515291A JP 2019529433 A5 JP2019529433 A5 JP 2019529433A5
Authority
JP
Japan
Prior art keywords
rirotomabu
satetorakisetan
administration
lymphoma
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019515291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529433A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/073336 external-priority patent/WO2018050851A1/en
Publication of JP2019529433A publication Critical patent/JP2019529433A/ja
Publication of JP2019529433A5 publication Critical patent/JP2019529433A5/ja
Pending legal-status Critical Current

Links

JP2019515291A 2016-09-16 2017-09-15 リロトマブおよび177Lu‐リロトマブ・サテトラキセタンを用いた非ホジキンリンパ腫の治療方法 Pending JP2019529433A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP16189191 2016-09-16
EP16189191.6 2016-09-16
EP17164164.0 2017-03-31
EP17164164 2017-03-31
EP17170641 2017-05-11
EP17170641.9 2017-05-11
EP17175768 2017-06-13
EP17175768.5 2017-06-13
PCT/EP2017/073336 WO2018050851A1 (en) 2016-09-16 2017-09-15 Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan

Publications (2)

Publication Number Publication Date
JP2019529433A JP2019529433A (ja) 2019-10-17
JP2019529433A5 true JP2019529433A5 (https=) 2020-10-22

Family

ID=59895313

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019515291A Pending JP2019529433A (ja) 2016-09-16 2017-09-15 リロトマブおよび177Lu‐リロトマブ・サテトラキセタンを用いた非ホジキンリンパ腫の治療方法

Country Status (14)

Country Link
US (2) US20190192703A1 (https=)
EP (1) EP3512881A1 (https=)
JP (1) JP2019529433A (https=)
KR (1) KR20190054113A (https=)
CN (1) CN109790219A (https=)
AU (1) AU2017327772A1 (https=)
BR (1) BR112019004838A2 (https=)
CA (1) CA3035268A1 (https=)
IL (1) IL265387A (https=)
MX (1) MX2019003029A (https=)
PH (1) PH12019550033A1 (https=)
RU (1) RU2019110955A (https=)
SG (2) SG11201901672RA (https=)
WO (1) WO2018050851A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2921020T3 (es) * 2017-08-04 2022-08-16 Bristol Myers Squibb Co Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo
EP3713607A1 (en) * 2017-11-22 2020-09-30 Nordic Nanovector ASA Radioimmunoconjugates in combination with other drugs as treatment against nhl
KR20240083769A (ko) 2022-12-05 2024-06-12 김원석 휴대할 수 있는 해수 정화 유닛용 물통

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU784971B2 (en) * 1999-08-11 2006-08-10 Biogen Inc. Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies
NO331080B1 (no) * 2010-01-29 2011-09-26 Nordic Nanovector As Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
CA2858964A1 (en) * 2011-12-13 2013-06-20 Nordic Nanovector As Chimeric therapeutic anti-cd37 antibodie hh1
KR102624023B1 (ko) * 2015-02-24 2024-01-11 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 결합-촉발된 전사 스위치 및 이들의 이용 방법

Similar Documents

Publication Publication Date Title
JP2017008088A5 (https=)
JP2016539156A5 (https=)
CL2012000313A1 (es) Composición de dosificación de película que comprende una matriz portadora, entre 2-16 mg de buprenorfina, entre 0,5-5 mg de naloxona y un tampón que proporciona un ph local entre 2-4; procedimiento de preparación; uso en el tratamiento de la dependencia de narcóticos en un usuario.
PH12015502317A1 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
NZ609201A (en) Means and methods for treating dlbcl
JP2008519047A5 (https=)
MY164352A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
RU2013102398A (ru) Лечение рака крови
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
RU2012157805A (ru) Способы лечения рака мочевого пузыря
MY173881A (en) Oral dosage forms of bendamustine and therapeutic use thereof
RU2019107011A (ru) Композиции апилимода и способы их применения
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
RU2017134443A (ru) Способ лечения с применением традипитанта
JP2019529433A5 (https=)
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
RU2015145997A (ru) Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат
RU2015102772A (ru) Бензодиазелипы для мелкоклеточного рака легкого
JP2016515619A5 (https=)
MX2010005198A (es) Composiciones liquidas que comprenden valsartan.
ATE543492T1 (de) Behandlung von lungenkrebs
FI3630177T3 (fi) Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle
Bruserud et al. High-dose etoposide in allogeneic stem cell transplantation
JP2014500259A (ja) 血液癌を処置する方法
RU2019110955A (ru) ЛЕЧЕНИЕ НЕХОДЖКИНСКОЙ ЛИМФОМЫ ЛИЛОТОМАБОМ И 177Lu-ЛИЛОТОМАБ САТЕТРАКСЕТАНОМ